Cargando…
Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis
BACKGROUND: There remains a critical need for more effective, safe, long-term treatments for cystic fibrosis (CF). Any successful therapeutic strategy designed to combat the respiratory pathology of this condition must address the altered lung physiology and recurrent, complex, polymicrobial infecti...
Autores principales: | Charrier, Cedric, Rodger, Catherine, Robertson, Jennifer, Kowalczuk, Aleksandra, Shand, Nicola, Fraser-Pitt, Douglas, Mercer, Derry, O’Neil, Deborah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260250/ https://www.ncbi.nlm.nih.gov/pubmed/25433388 http://dx.doi.org/10.1186/s13023-014-0189-2 |
Ejemplares similares
-
Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum
por: Devereux, Graham, et al.
Publicado: (2015) -
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex
por: Fraser-Pitt, Douglas, et al.
Publicado: (2016) -
An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis
por: Devereux, Graham, et al.
Publicado: (2016) -
Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection
por: Fraser-Pitt, Douglas J., et al.
Publicado: (2018) -
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial
por: Devereux, Graham, et al.
Publicado: (2020)